Diabetologia

, Volume 38, Issue 11, pp 1307–1312

Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects

Authors

  • R. L. Chaiken
    • Department of Medicine, Division of EndocrinologyState University of New York, Health Science Center
  • M. Eckert-Norton
    • Department of Medicine, Division of EndocrinologyState University of New York, Health Science Center
  • R. Pasmantier
    • Department of Medicine, Division of EndocrinologyState University of New York, Health Science Center
  • G. Boden
    • Department of Medicine, Division of Endocrinology and MetabolismTemple University School of Medicine
  • I. Ryan
    • Department of Medicine, Division of Endocrinology and MetabolismTemple University School of Medicine
  • R. A. Gelfand
    • Experimental Medicine, Central Research DivisionPfizer Inc.
  • H. E. Lebovitz
    • Department of Medicine, Division of EndocrinologyState University of New York, Health Science Center
Originals

DOI: 10.1007/BF00401763

Cite this article as:
Chaiken, R.L., Eckert-Norton, M., Pasmantier, R. et al. Diabetologia (1995) 38: 1307. doi:10.1007/BF00401763

Summary

Insulin resistance is a significant pathogenetic factor in the development of non-insulin-dependent diabetes mellitus (NIDDM). A new class of drugs, the thiazolidinediones, have been shown to lower blood glucose levels without stimulating insulin secretion. We report the metabolic effect of the thiazolidinedione, darglitazone, in obese NIDDM subjects. Nineteen subjects were enrolled in a doubleblind placebo-controlled study in which 25 mg of darglitazone was given once a day for 14 days. Nine subjects received the active drug and ten subjects received placebo. Darglitazone-treated subjects showed; 1) a decrease in 24-h plasma glucose area under the curve from 292.8±31.2 to 235.2±21.6 mmol · h−1 · l−1p=0.002; 2) a decrease in 24-h serum insulin area under the curve from 1027.2±254.4 to 765.6±170.4 ΜU · h−1 · l−1p=0.045; 3) a decrease in 24-h non-esterified fatty acid area under the curve from 1900±236 to 947±63 g · h−1 · l−1p=0.002; 4) a decrease in mean 24-h serum triglyceride by 25.9±6.2% as compared to − 3.9±4.8% for the placebo-treated group, p=0.012. Placebo-treated subjects showed no change in their metabolic parameters after treatment. Thus, darglitazone is effective in increasing insulin effectiveness in obese NIDDM subjects. The potential for this and similar drugs to treat or prevent NIDDM as well as the insulin-resistance syndrome needs to be explored.

Key words

Non-insulin-dependent diabetes mellitusdarglitazoneinsulin sensitizer

Abbreviations

NIDDM

Non-insulin-dependent diabetes mellitus

NEFA

non-esterified fatty acids

IVGTT

intravenous glucose tolerance test

AUC

area under the curve

Copyright information

© Springer-Verlag 1995